Our data indicate that application of TRAIL-coated oncolytic adenovirus vectors in combination with Rh2 may be an option for the treatment of relapsed AML or patients who are ineligible for intensive therapy. This evidence concerns the gene TNFSF10 and acute myeloid leukemia.